Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Junshi Starts Global Phase III Trial of COVID-19 Therapy

publication date: Mar 16, 2022

Shanghai Junshi Bio has dosed the first patient in an international Phase III trial of VV116 to treat moderate to severe COVID-19. VV116 is a novel oral nucleoside analog anti-SARS-CoV-2 drug designed to inhibit replication of SARS-CoV-2. The candidate was developed by a number of China Institutes, an Uzbekistan institute, Suzhou Vigonvita Life Sciences and Junshi. In preclinical studies, the drug showed antiviral activity against the original SARS-CoV-2 strain and all variants to date. It was approved for use in Uzbekistan last year. More details....

Stock Symbols: (HK: 1877; SHA: 688180)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here